The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 18 and 19 October 2017 it purchased 256,520 and 193,100 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.075p per Ordinary Share (the “Purchase”) and on 20 October it purchased 119,636 ordinary shares of 1p each at a price of 3.15p per Ordinary Share. Following the Purchase, Vulpes has a total direct and indirect interest in 55,012,971 equivalent to 18.64% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,012,971 Ordinary Shares of the Company representing 18.64% of the issued share capital of the Company.